Ascendis Pharma A/S
ASND · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $214 | $158 | $101 | $174 |
| % Growth | 35.2% | 56.6% | -42% | – |
| Cost of Goods Sold | $22 | $31 | $18 | $14 |
| Gross Profit | $191 | $127 | $83 | $160 |
| % Margin | 89.5% | 80.1% | 82.6% | 91.9% |
| R&D Expenses | $67 | $72 | $87 | $79 |
| G&A Expenses | $0 | $106 | $96 | $79 |
| SG&A Expenses | $113 | $106 | $96 | $79 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $2 | $5 | $1 |
| Operating Expenses | $180 | $180 | $188 | $160 |
| Operating Income | $11 | -$53 | -$104 | $0 |
| % Margin | 5.1% | -33.5% | -103.2% | 0.2% |
| Other Income/Exp. Net | -$68 | $18 | $11 | -$38 |
| Pre-Tax Income | -$57 | -$35 | -$94 | -$37 |
| Tax Expense | $4 | $4 | $1 | $1 |
| Net Income | -$61 | -$39 | -$95 | -$38 |
| % Margin | -28.5% | -24.6% | -93.7% | -22.1% |
| EPS | -1 | -0.64 | -1.58 | -0.64 |
| % Growth | -56.3% | 59.5% | -146.9% | – |
| EPS Diluted | -1 | -0.82 | -1.58 | -0.64 |
| Weighted Avg Shares Out | 61 | 60 | 60 | 60 |
| Weighted Avg Shares Out Dil | 61 | 64 | 60 | 60 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $55 | $29 | -$67 |
| Interest Expense | $0 | $33 | $45 | -$57 |
| Depreciation & Amortization | $4 | $4 | $5 | $4 |
| EBITDA | -$53 | $2 | -$44 | -$38 |
| % Margin | -25% | 1.5% | -43.8% | -21.8% |